Leadership of the Fox Chase Cancer Center is under the direction of its President and Chief Executive Officer, Michael V. Seiden, M.D., Ph.D.;the Deputy Director (DD) and Chief Scientific Officer (CSO),Jonathan Chernoff, M.D., Ph.D.;the Associate Director for Academics (AD-A) and Chief Academic Officer (CAO), J. Robert Beck M.D.;the Associate Director for Networks (AD-N) and Chief Network Officer (CNO), Paul Engstrom, M.D.;and the Associate Director for Clinical Research (AD-CR), Massimo Cristofanilli, M.D, (see Cancer Center Organizational chart on the cover of this section). Seiden has complete authority over all activities of the Center including faculty appointments. Center space and institutional monies. He reports to the Board of Directors. The DD is responsible for the Center's Research Programs, Shared Resources and Research Administration. The AD-A manages the faculty appointment and promotion process, training programs, mentoring. Institutional Review Board, and extramural relationships. The AD-N is responsible for disseminating best practices and working with the Center's extensive network of affiliates. The AD-CR has responsibility for the Protocol Office and clinical research management, including the Research Review Committee. This CCSG-funded Cancer Center leadership group is a subset of Fox Chase Cancer Center's Senior Leadership Council (SLC), which meets weekly to direct all activities of the Center. Included in the SLC are the Chief Operating Officer, Chief Financial Officer, Chief Development Officer, and the Senior Vice President for Business Development and Clinical Operations. The five Cancer Center leaders establish overall research priorities, foster the continued integration of scientific and medical programs, discuss and set recruiting priorities, create senior level search committees, review and approve faculty promotions, and discuss current issues facing Fox Chase Cancer Center and its scientific faculty and staff. In addition, Seiden meets with the DD and AD-A at least weekly (usually daily). The team also makes decisions concerning optimal use of CCSG resources. Examples include reorganizing the Research Programs and Shared Resources, recruiting senior leaders {e.g., Cristofanilli), and empowering Program and Resource leaders. Senior Leadership has recruited 21 faculty since Seiden's assuming the Presidency in 2007.

Public Health Relevance

The Senior Leadership of the Cancer Center is responsible for the organization and administration of the Center and the CCSG. As such the composition, function and effectiveness of the Senior Leadership has immense relevance to the CCSG as a whole.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
7P30CA006927-50
Application #
8475329
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$1,851,077
Indirect Cost
$1,670,117
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Boland, Patrick M; Meyer, Joshua E; Berger, Adam C et al. (2016) Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol :
Heckman, Carolyn J; Handorf, Elizabeth A; Darlow, Susan D et al. (2016) An Online Skin Cancer Risk-Reduction Intervention for Young Adults: Mechanisms of Effects. Health Psychol :
Meropol, Neal J; Wong, Yu-Ning; Albrecht, Terrance et al. (2016) Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials. J Clin Oncol 34:469-78
Hayakawa, K; Formica, A M; Colombo, M J et al. (2016) Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells. Leukemia 30:1510-9
Tan, Yinfei; Xin, Xiaoban; Coffey, Francis J et al. (2016) Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. J Cell Physiol 231:1142-50
Duong-Ly, Krisna C; Devarajan, Karthik; Liang, Shuguang et al. (2016) Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases. Cell Rep 14:772-81
Meeker, Caitlin R; Geynisman, Daniel M; Egleston, Brian L et al. (2016) Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. J Oncol Pract 12:e755-64
Geynisman, Daniel M; Handorf, Elizabeth; Wong, Yu-Ning et al. (2016) Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Med 5:192-9
Kurimchak, Alison M; Shelton, Claude; Duncan, Kelly E et al. (2016) Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep 16:1273-86
Borczuk, Alain C; Pei, Jianming; Taub, Robert N et al. (2016) Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 17:328-35

Showing the most recent 10 out of 884 publications